When Laws Pass, Pot Stocks Soar

Michael A. Robinson

Back in September, when I made "Four High-Profit Predictions About Pot Stock Investing in 2018," I recommended investors get prepared for what I believe will be one of the most significant moneymaking triggers we've ever seen…

I'm talking about California, of course, and its upcoming Jan. 1, 2018, total legalization of marijuana.

That means medical patients and adult recreational users alike will be able to use cannabis and buy from legitimate, regulated businesses starting Jan. 1 in California.

Now, as you know, legal marijuana is already booming in the 29 U.S. states where recreational and/or medical cannabis is legal.

But California, the nation's most populous state and, indeed, the world's sixth-largest economy, is in a class by itself.

Total legalization here could open up the money floodgates for folks who own the right stocks.

So let's look at what we know so far… and why this is huge news for small pot stocks.

New Laws Put the Market in Much Clearer Focus

So, we knew legalization in California was going to be "big," and now that the California Bureau of Cannabis Control has released 276 pages of regulations that the Golden State's marijuana businesses must abide by next year, we've got a better idea of where this is going.

Because, as one of my "rules" for cannabis investing goes, "When laws pass, pot stocks soar."

New Legislation: Cannabis gains could blow the doors off anything we've seen so far. Click here for more…

The numbers here are absolutely staggering. California's market is bigger than any U.S. state, and even than all of Canada. We're talking $7 billion a year – just to start.

Arcview Group expects revenue to jump to more than $21 billion by 2021.

I'll show you why the Golden State might as well change its name to the Green State; it's about to become ground zero for pot stock profits.

These regulations should be great for California's weed market. They do mostly what I expected, although, as you'll see, there are a few welcome surprises, too.

They're largely common-sense steps designed to make the market work and keep users and non-users alike safe. That's great news for investors.

Take a look…

Michael A. Robinson

About the Author

Browse Michael's articles | View Michael's research services

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

• He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
• He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
• As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

… Read full bio